Under Consent Decree, J&J Delays Full Return Of Recalled OTCs Until 2012

By Dan Schiff / Email the Author / “The Tan Sheet” Apr. 25, 2011, Vol. 19, No. 17
Business & Finance / Word Count: 842 / Article # 05110425004

Executive Summary

Johnson & Johnson pushes back to 2012 the target for returning its full slate of recalled OTC drugs to market as it adjusts to operating under a consent decree with FDA and the Department of Justice.

Purchase this Article

$50.00 Buy Now

For $50.00, purchase this 842-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Under Consent Decree, J&J Delays Full Return Of Recalled OTCs Until 2012

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to “The Tan Sheet” will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

Under Consent Decree, J&J Delays Full Return Of Recalled OTCs Until 2012

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 12

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article